Fisher Asset Management LLC Reduces Position in Sanofi $SNY

Fisher Asset Management LLC lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 3.5% in the 4th quarter, Holdings Channel reports. The fund owned 12,140,615 shares of the company’s stock after selling 438,131 shares during the quarter. Fisher Asset Management LLC’s holdings in Sanofi were worth $588,334,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of SNY. Brighton Jones LLC grew its holdings in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after purchasing an additional 1,869 shares during the period. AQR Capital Management LLC grew its holdings in shares of Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after purchasing an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares during the period. Sivia Capital Partners LLC grew its holdings in shares of Sanofi by 5.4% in the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Sanofi by 36.1% in the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after purchasing an additional 875 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Argus raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Finally, Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $51.00.

Sanofi Price Performance

Shares of SNY opened at $44.29 on Monday. The stock has a market capitalization of $108.02 billion, a PE ratio of 12.37, a P/E/G ratio of 1.09 and a beta of 0.35. Sanofi has a 1 year low of $42.33 and a 1 year high of $53.03. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. The company’s 50-day simple moving average is $45.58 and its 200-day simple moving average is $47.21.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be given a dividend of $2.4225 per share. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 559.0%. The ex-dividend date of this dividend is Monday, May 4th. Sanofi’s dividend payout ratio is currently 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.